Table 3.
CCI, 10 most frequent comorbidities based on ICD-10-GM code, and death rate during the 12 months follow-up
| Allo-HSCT | SOT | |||||||
|---|---|---|---|---|---|---|---|---|
| All patients n = 226 |
CMV n = 66 |
No CMV n = 160 |
p value | All patients n = 250 |
CMV n = 42 |
No CMV n = 208 |
p value | |
| CCIa, mean (SD) | 5.3 (2.9) | 5.5 (2.6) | 5.2 (3.1) | 0.262 | 5.8 (3.1) | 6.0 (3.0) | 5.7 (3.1) | 0.474 |
| I10.- Essential (primary) hypertension | 123 (54.4) | 40 (60.6) | 83 (51.9) | 0.244 | 206 (82.4) | 36 (85.7) | 170 (81.7) | 0.660 |
| T86.- Failure and rejection of transplanted organs and tissuesb | 118 (52.2) | 46 (69.7) | 72 (45.0) | 0.001 | 171 (68.4) | 36 (85.7) | 135 (64.9) | 0.010 |
| E87.- Other disorders of fluid, electrolyte and acid–base balance | 135 (59.7) | 50 (75.8) | 85 (53.1) | 0.002 | 149 (59.6) | 34 (81.0) | 115 (55.3) | 0.002 |
| D69.- Purpura and other hemorrhagic conditionsc | – | – | – | – | 67 (26.8) | 15 (35.7) | 52 (25.0) | 0.181 |
| D70.- Agranulocytosisc | – | – | – | – | 29 (11.6) | 8 (19.0) | 21 (10.1) | 0.113 |
| D61.- Other aplastic anemiasc | – | – | – | – | 10 (4.0) | 4 (9.5) | 6 (2.9) | 0.067 |
| E78.- Disorders of lipoprotein metabolism and other lipidemias | 40 (17.7) | 9 (13.6) | 31 (19.4) | 0.344 | 136 (54.4) | 26 (61.9) | 110 (52.9) | 0.312 |
| D68.- Other coagulation defects | 62 (27.4) | 23 (34.8) | 39 (24.4) | 0.076 | 114 (45.6) | 19 (45.2) | 95 (45.7) | 0.548 |
| N39.- Other disorders of urinary system | 76 (33.6) | 34 (51.5) | 42 (26.3) | < 0.001 | 97 (38.8) | 17 (40.5) | 80 (38.5) | 0.863 |
| E83.- Disorders of mineral metabolism | 52 (23.0) | 21 (31.8) | 31 (19.4) | 0.056 | 91 (36.4) | 16 (38.1) | 75 (36.1) | 0.861 |
| Death, n (%) | 81 (35.8) | 25 (37.9) | 56 (35.0) | 0.761 | 27 (10.8) | 5 (11.9) | 22 (10.6) | 0.787 |
Allo-HSCT allogeneic hematopoietic stem cell transplantation, CCI Charlson Comorbidity Index, PY patient-year, SD standard deviation, SOT solid organ transplantation
aCharlson comorbidity index, not adjusted for age
bICD-10-GM code includes documentation of graft-versus-host disease, transplant dysfunction, delayed integration of transplant, as well as transplant failure and rejection
cDiagnoses generally present in HSCT patients not shown for respective patient group